Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,561.59
(
0.55%
)
US TECH 100
29,436.00
(
0.88%
)
Dow Jones
50,664.89
(
0.04%
)
Brent Oil
91.99
(
-0.49%
)
Bitcoin
73,218.30
(
-2.23%
)
News Focus
News Focus
Post# of 257650
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123030
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: aslan2772 post# 136348

Tuesday, 09/03/2013 5:05:28 PM

Tuesday, September 03, 2013 5:05:28 PM

Post# of 257650
SRDX realigns top management:

http://finance.yahoo.com/news/surmodics-announces-organizational-changes-203000837.html

I owned SRDX in its heyday when it was deriving substantial royalties from JNJ’s now-defunct Cypher stent. However, after SRDX failed in various ophthalmology programs—including a program to deliver sustain-release Lucentis via an implant (#msg-57844827, #msg-32241114)—I lost interest and stopped following the company.

With an enterprise value of ~$250M, perhaps this solidly profitable company is worth another look.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today